The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability

In spite of decades of epidemiological research, the etiology and causal patterns for many common diseases, such as breast and colon cancer or neurodegenerative diseases, are still largely unknown. Such chronic diseases are likely to have an environmental origin. However, "environmental" risks have been often elusive in epidemiological studies. This is a conundrum for current epidemiological research. On the other side, the relative contribution of genes to chronic diseases, as emerging from GWAS, seems to be modest (15-50% increase in disease risk). What is yet to be explored extensively is a model of disease based on long-term effects of low doses of environmental exposures, incorporating both genetic and acquired susceptibility ("clinical vulnerability"), and the cumulative effects of different exposures. Such a disease model would be compatible with the weak associations found by GWAS and the still elusive role of many (low-level) environmental exposures. We also propose that the introduction of "-omic" high-throughput technologies, such as transcriptomics, proteomics and metabolomics, may provide, in the next years, powerful tools to investigate early effects of environmental exposures and understand the etiology of common diseases better, according to the "clinical vulnerability model". The development of "-omics", in spite of current limitations and lack of sound validation, could greatly contribute to the elucidation of the disease model we propose.

[1]  N. Holbrook,et al.  Oxidants, oxidative stress and the biology of ageing , 2000, Nature.

[2]  J. Pouysségur,et al.  The hypoxia‐inducible‐factor hydroxylases bring fresh air into hypoxia signalling , 2006, EMBO reports.

[3]  A. Bird,et al.  Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. , 1999, Genes & development.

[4]  F. Clavel-Chapelon,et al.  Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study , 2005, BMJ : British Medical Journal.

[5]  S. Chellappan HOG on the Promoter: Regulation of the Osmotic Stress Response , 2001, Science's STKE.

[6]  L. Hou,et al.  Changes in DNA methylation patterns in subjects exposed to low-dose benzene. , 2007, Cancer research.

[7]  D. Leibfritz,et al.  Visualizing metabolic changes in breast‐cancer tissue using 1H‐NMR spectroscopy and self‐organizing maps , 2003, NMR in biomedicine.

[8]  R. Jirtle,et al.  Environmental epigenomics and disease susceptibility , 2007, Nature Reviews Genetics.

[9]  David J Hunter,et al.  Genomics and proteomics in epidemiology: treasure trove or "high-tech stamp collecting"? , 2006, Epidemiology.

[10]  J. Chen,et al.  Global Gene Expression Profiling in Whole-Blood Samples from Individuals Exposed to Metal Fumes , 2004, Environmental health perspectives.

[11]  N. Rothman,et al.  Use of 'omic' Technologies to Study Humans Exposed to Benzene , 2005 .

[12]  J. Nicholson,et al.  NMR and pattern recognition studies on liver extracts and intact livers from rats treated with alpha-naphthylisothiocyanate. , 2002, Biochemical pharmacology.

[13]  M. Gail,et al.  The promise and peril of surrogate end points in cancer research , 2002, Nature Reviews Cancer.

[14]  C. Gallou-Kabani,et al.  Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. , 2005, Diabetes.

[15]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[16]  N. Barbarroja,et al.  Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases , 2008, Lupus.

[17]  Bert Brunekreef,et al.  Long-Term Exposure to Traffic-Related Air Pollution and Lung Cancer Risk , 2008, Epidemiology.

[18]  Steven R. Tannenbaum,et al.  Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens , 1994, Nature.

[19]  F. Clavel-Chapelon,et al.  Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study , 2007, Environmental health : a global access science source.

[20]  Duncan C Thomas,et al.  High-volume "-omics" technologies and the future of molecular epidemiology. , 2006, Epidemiology.

[21]  Eunil Lee,et al.  Proteomic analysis of plasma proteins of workers exposed to benzene. , 2004, Mutation research.

[22]  Nathaniel Rothman,et al.  Hematotoxicity in Workers Exposed to Low Levels of Benzene , 2004, Science.

[23]  Marina Pollán,et al.  Sources of error and its control in studies on the diagnostic accuracy of “‐omics” technologies , 2009, Proteomics. Clinical applications.

[24]  Nilanjan Chatterjee,et al.  Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Paolo Vineis,et al.  Dose‐response relationship in tobacco‐related cancers of bladder and lung: A biochemical interpretation , 2004, International journal of cancer.

[26]  A. Feinberg,et al.  The emerging science of epigenomics. , 2006, Human molecular genetics.

[27]  Sander Greenland,et al.  Modern Epidemiology 3rd edition , 1986 .

[28]  角田 亮子,et al.  プロダクトレビュー Lippincott Williams & Wilkinsの電子ジャーナル , 2007 .

[29]  H. R. Anderson,et al.  Particulate air pollution and hospital admissions for cardiorespiratory diseases: are the elderly at greater risk? , 2003, European Respiratory Journal.

[30]  Adrian Bird,et al.  Perceptions of epigenetics , 2007, Nature.

[31]  E Holmes,et al.  NMR and pattern recognition studies on the time-related metabolic effects of alpha-naphthylisothiocyanate on liver, urine, and plasma in the rat: an integrative metabonomic approach. , 2001, Chemical research in toxicology.

[32]  Trygve O. Tollefsbol,et al.  Aging, cancer and nutrition: the DNA methylation connection , 2003, Mechanisms of Ageing and Development.

[33]  E. Diamandis Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[34]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[35]  R. Case,et al.  Tumours Of The Urinary Bladder in Workmen Engaged in the Manufacture and Use Of Certain Dyestuff Intermediates In The British Chemical Industry. Part I. The Role Of Aniline, Benzidine, Alpha-Naphthylamine, And Beta-Naphthylamine , 1954, British journal of industrial medicine.

[36]  S. Dawsey,et al.  Validation of intermediate end points in cancer research. , 1990, Journal of the National Cancer Institute.

[37]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[38]  F Baganz,et al.  Systematic functional analysis of the yeast genome. , 1998, Trends in biotechnology.

[39]  Ian J. Brown,et al.  Human metabolic phenotype diversity and its association with diet and blood pressure , 2008, Nature.

[40]  R. Gomis,et al.  Proteomics in obesity research , 2009, Proteomics. Clinical applications.

[41]  M. Esteller Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[42]  C. Wild Complementing the Genome with an “Exposome”: The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology , 2005, Cancer Epidemiology Biomarkers & Prevention.

[43]  A. Baccarelli,et al.  Global DNA Hypomethylation Is Associated with High Serum-Persistent Organic Pollutants in Greenlandic Inuit , 2008, Environmental health perspectives.

[44]  F. Blanco,et al.  Proteomic characterization of human normal articular chondrocytes: A novel tool for the study of osteoarthritis and other rheumatic diseases , 2005, Proteomics.

[45]  M. Waalkes,et al.  Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  Ishtiaq Rehman,et al.  The Use of Proteomics in Urological Research , 2005 .

[47]  Antonella Zanobetti,et al.  Rapid DNA methylation changes after exposure to traffic particles. , 2009, American journal of respiratory and critical care medicine.

[48]  L. Wallrath,et al.  Connections between epigenetic gene silencing and human disease. , 2007, Mutation research.

[49]  Paolo Vineis,et al.  Causal models in epidemiology: past inheritance and genetic future , 2006, Environmental health : a global access science source.

[50]  Jaco Vangronsveld,et al.  Environmental exposure to cadmium and risk of cancer: a prospective population-based study. , 2006, The Lancet. Oncology.

[51]  Marina Pollán,et al.  QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of '-omics'-based technologies. , 2008, Clinical biochemistry.

[52]  E. Calvo,et al.  Proteomics: New insights into rheumatic diseases , 2009, Proteomics. Clinical applications.

[53]  Alan Hutson,et al.  Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.

[54]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.